Microcap Ledger Adicet Bio, Inc. $ACET
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Boston, MA
- Fiscal year end
- December 26
- Shares outstanding
- 9,361,490 [10-Q 2026-08-05]
What the company doesAI summary of filing
Adicet Bio is a clinical-stage biotechnology company developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company manufactures off-the-shelf gamma delta T cells engineered with chimeric antigen receptors (CARs) from unrelated donors. Its lead product candidate, prulacabtagene leucel (prula-cel), targeting CD20, is in Phase 1 clinical trials for multiple autoimmune indications including lupus nephritis, systemic lupus erythematosus, systemic sclerosis, and rheumatoid arthritis; the company also is advancing ADI-212, a gene-edited gamma delta T cell candidate targeting prostate-specific membrane antigen for metastatic castration-resistant prostate cancer, with regulatory filing expected in the third quarter of 2026 and patient enrollment anticipated in the fourth quarter of 2026. The company is pre-revenue and generates no product revenue from commercial sales. [10-K 2026-03-12]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$41.60M | −$41.31M | $33.13M | [10-Q 2026-08-05] |
| FY ended Dec 2025 | — | −$116.80M | −$95.25M | $38.92M | [DEF 14A 2026-04-29] |
| FY ended Dec 2024 | — | −$117.12M | −$92.38M | $56.49M | [DEF 14A 2026-04-29] |
- Quarterly cash burn
- −$20.66M
- Cash runway Estimate
- ~4.8 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2025-03-03 | 82,685,750 | [10-K 2025-03-06] |
| 2025-05-02 | 82,709,625 | [10-Q 2025-05-06] |
| 2025-08-05 | 83,253,779 | [10-Q 2025-08-07] |
| 2025-11-03 | 153,255,581 | [10-Q 2025-11-05] |
| 2026-03-10 | 9,596,407 | [10-K 2026-03-12] |
| 2026-05-11 | 9,348,236 | [10-Q 2026-05-13] |
| 2026-05-19 | 9,348,236 | [10-K/A 2026-05-20] |
| 2026-08-03 | 9,361,490 | [10-Q 2026-08-05] |
- Shelf registration
- S-3 filed 2026-03-12; declared effective 2026-03-23 [S-3 2026-03-12]
Listing status
Current status: 2 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-10-07. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2025-10-07 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-10-07] |
| 2025-04-11 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-04-11] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-28 | 8-K | Regulation FD disclosure; Other events |
| 2026-09-08 | 8-K | Regulation FD disclosure |
| 2026-09-01 | 8-K | Regulation FD disclosure |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-05 | 10-Q | Quarterly report |
| 2026-08-05 | 8-K | Results of operations |
| 2026-06-18 | 8-K | Shareholder vote results |
| 2026-05-20 | 10-K/A | Amended report |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-13 | 10-Q | Quarterly report |
| 2026-05-13 | 8-K | Results of operations |
| 2026-04-29 | DEF 14A | Proxy statement |
Alerts for $ACET
Email me when Adicet Bio, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.